Clinical trials: Plaque Psoriasis.
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00338754
- Testing
- Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks
- Where
- 8 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Abbott
Plaque Psoriasis
Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test
Evaluation of safety, pharmacokinetics, and anti-psoriatic efficacy to assess SOR007 Ointment in topical formulations
- Trial name
- NCT03004339
- Testing
- SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- DFB Soria, LLC
Psoriatic Plaque
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis
This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114…
- Trial name
- NCT03630939
- Testing
- ESR-114
- Where
- 10 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Escalier Biosciences B.V.
Psoriasis
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
- Trial name
- NCT02407041
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Galectin Therapeutics Inc.
Psoriasis
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis.
- Trial name
- EMBRACE 1 (NCT04305327)
- Testing
- Brodalumab, Ustekinumab
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 12 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis
Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis
- Trial name
- NCT02462122
- Testing
- IDP-118 Lotion, IDP-118 Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 215 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Stable Plaque Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02445807
- Testing
- DFD06-Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 265 people
- Sponsor
- Promius Pharma, LLC
Psoriasis
A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and tolerability of CNTO 1959 following a single subcutaneous (SC, under the skin) dose administered to Japanese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT01484587
- Testing
- CNTO 1959
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Janssen Pharmaceutical K.K.
Plaque Psoriasis
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT02367911
- Testing
- 122-0551 Foam, Vehicle Foam
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis.
- Trial name
- NCT07719530
- Testing
- The SHR-1139 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Plaque Psoriasis
A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07765628
- Testing
- HS-20118
- Volunteers
- 120 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645892
- Testing
- adalimumab
- Volunteers
- 32 people
- Sponsor
- Abbott
Plaque Psoriasis
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with…
- Trial name
- NCT03930186
- Testing
- Apremilast, Topical Therapy
- Where
- 56 sites in Germany, Japan
- Volunteers
- 152 people
- Sponsor
- Amgen
Moderate-to-severe Plaque Psoriasis
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
- Trial name
- SPARROW (NCT06142357)
- Testing
- Secukinumab
- Where
- 16 sites in Russia
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
- Trial name
- NCT07449702
- Testing
- ORKA-001
- Where
- 39 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Oruka Therapeutics, Inc.
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.